Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00875238 · ClinicalTrials.gov registry record

Side Effects Involving the Heart in Women With Breast Cancer Receiving Doxorubicin and Trastuzumab

A clinical trial of Breast Cancer and Cardiac Toxicity, sponsored by Vanderbilt University.

Completed
Registry status
133
Enrollment target
4
Study locations

NCT00875238 is a study of Breast Cancer and Cardiac Toxicity that has completed, run by Vanderbilt University. The registered enrollment target is 133 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (95% lower). The trial reports 4 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00875238, a study of Breast Cancer and Cardiac Toxicity, has completed, sponsored by Vanderbilt University.

COMPLETED
Registry status
133 participants
Enrollment target
4
Study locations

Study Summary

RATIONALE: Studying samples of blood and tissue in the laboratory from women receiving doxorubicin and trastuzumab for breast cancer may help doctors learn more about changes that occur in DNA and identify biomarkers for increased risk of cardiac effects. PURPOSE: This clinical trial is studying side effects involving the heart in women with breast cancer receiving doxorubicin and trastuzumab.

Conditions Studied

Breast Cancer Cardiac Toxicity Cardiovascular Complications

Interventions

  • OTHER laboratory biomarker analysis
  • OTHER questionnaire administration
  • BIOLOGICAL trastuzumab
  • GENETIC polymorphism analysis
  • DRUG doxorubicin hydrochloride

Study Locations (4)

Tennessee

  • Vanderbilt Heart One Hundred Oaks - Nashville
  • MBCCOP - Meharry Medical College - Nashville - Nashville
  • Vanderbilt-Ingram Cancer Center - Nashville

Kentucky

  • University of Louisville James Graham Brown Cancer Center - Louisville

Trial Details

FieldValue
Enrollment Target 133 participants
Start Date 2008-06
Est. Completion 2015-03

Sponsor

Vanderbilt University

430 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00875238

The ClinicalTrials.gov registry entry for NCT00875238 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 133 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (95% lower). The listed sponsor is Vanderbilt University, which has 430 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which laboratory biomarker analysis is the first listed.

NCT00875238 reports 4 study locations spanning 2 distinct geographic areas - top geographies include Tennessee, Kentucky.

Frequently Asked Questions

What is clinical trial NCT00875238 about?

NCT00875238 is a clinical study titled "Side Effects Involving the Heart in Women With Breast Cancer Receiving Doxorubicin and Trastuzumab". RATIONALE: Studying samples of blood and tissue in the laboratory from women receiving doxorubicin and trastuzumab for breast cancer may help doctors learn more about changes that occur in DNA and identify biomarkers for increased risk of cardiac effects. PURPOSE: This clinical trial is studying si...

What is the current status of trial NCT00875238?

This trial is currently completed. The enrollment target is 133 participants. The study started on 2008-06. Estimated completion is 2015-03.

What conditions does trial NCT00875238 study?

This clinical trial studies the following conditions: Breast Cancer, Cardiac Toxicity, Cardiovascular Complications.

What interventions are being tested in trial NCT00875238?

The interventions under investigation include: laboratory biomarker analysis (OTHER), questionnaire administration (OTHER), trastuzumab (BIOLOGICAL), polymorphism analysis (GENETIC), doxorubicin hydrochloride (DRUG).

Who is sponsoring clinical trial NCT00875238?

This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00875238 being conducted?

This trial has 4 study locations across Kentucky, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer

All registered trials for this condition

Cardiac Toxicity

All registered trials for this condition

Kentucky

All trials with a study site in Kentucky

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.